Medicare Enrolled

Dr. Ofobuike Okani, M.D.

Medical Oncology · Waco, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
6520 HORIZON CIR, Waco, TX 76712
2547554460
In practice since 2006 (19 years)
NPI: 1821104431 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Okani from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Okani? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Okani

Dr. Ofobuike Okani is a medical oncology in Waco, TX, with 19 years in practice. Based on federal Medicare data, Dr. Okani performed 33,653 Medicare services across 1,501 unique beneficiaries.

Between the years covered by Open Payments, Dr. Okani received a total of $2,917 from 39 pharmaceutical and/or device companies across 68 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Okani is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice▲ Top 27% volume in TX$ $2,917 industry payments

Medicare Practice Summary

Medicare Utilization ↗
33,653
Medicare services
Top 27% in TX for medical oncology
1,501
Unique beneficiaries
$5
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~1,771 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Iron infusion (Feraheme)20,400$0$5
Anti-nausea injection (fosaprepitant)5,100$0$5
Contrast dye for imaging (iodine-based)2,383$0$3
Dexamethasone injection (steroid)1,118$0$1
Blood draw (venipuncture)1,040$8$20
Complete blood count (CBC) with differential827$8$36
Office visit, established patient (30-39 min)719$88$368
Anti-nausea injection (Aloxi/palonosetron)400$1$114
Injection of additional new drug or substance into vein210$12$108
Microscopic examination for white blood cells with manual cell count181$4$22
Complete blood count (CBC), automated181$6$34
Administration of chemotherapy into vein, 1 hour or less167$96$707
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less157$22$157
Injection, zoledronic acid, 1 mg92$6$431
Drug injection, under skin or into muscle85$11$96
Administration of chemotherapy into vein, each additional hour82$21$161
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less79$46$313
Injection, diphenhydramine hcl, up to 50 mg70$1$7
New patient office visit, complex (60-74 min)57$153$709
Office visit, established patient, complex (40-54 min)39$120$496
Administration of additional new drug or substance into vein, 1 hour or less37$47$344
Office visit, established patient (20-29 min)35$50$250
Infusion, normal saline solution , 1000 cc33$2$19
Unclassified drugs31$17$88
Nuclear medicine study from skull base to mid-thigh with ct scan27$1,089$4,802
Irrigation of implanted venous access drug delivery device26$18$114
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries26$87$657
CT scan of abdomen and pelvis with contrast21$142$1,067
Red blood count, automated test18$4$23
Initial hospital admission, high complexity12$133$694
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
61.4% high complexity
29.0% medium
9.6% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$2,917
Total received (2018-2024)
Avg $417/year across 7 years
Bottom 45% in TX for medical oncology
39
Companies
68
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$2,529 (86.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$388 (13.3%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$473
2023
$498
2022
$221
2021
$37
2020
$280
2019
$565
2018
$844

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$282
E.R. Squibb & Sons, L.L.C.
$281
Sirtex Medical Inc
$151
PharmaEssentia USA Corporation
$135
ABBVIE INC.
$124
Janssen Scientific Affairs, LLC
$122
Novartis Pharmaceuticals Corporation
$112
Clovis Oncology, Inc.
$110
Astellas Pharma US Inc
$104
Janssen Products, LP
$100
Taiho Oncology, Inc.
$98
Merck Sharp & Dohme LLC
$97
ADC Therapeutics America, Inc.
$96
Seattle Genetics, Inc.
$95
Merck Sharp & Dohme Corporation
$95
Verastem, Inc.
$94
Janssen Biotech, Inc.
$79
Pharmacyclics LLC, An AbbVie Company
$77
GENZYME CORPORATION
$65
Kite Pharma, Inc.
$63
Lilly USA, LLC
$52
Rigel Pharmaceuticals, Inc.
$51
Daiichi Sankyo Inc.
$51
Seagen Inc.
$48
Tempus AI, Inc
$36
Mirati Therapeutics, Inc.
$34
Regeneron Healthcare Solutions, Inc.
$29
Karyopharm Therapeutics Inc.
$25
Gilead Sciences, Inc.
$25
Adaptive Biotechnologies Corporation
$24
TAIHO ONCOLOGY, INC.
$23
ARRAY BIOPHARMA INC
$22
Incyte Corporation
$21
SOBI, INC
$20
Stemline Therapeutics Inc.
$19
Blueprint Medicines Corporation
$17
AVEO Pharmaceuticals, Inc.
$15
EMD Serono, Inc.
$13
Acrotech Biopharma LLC
$12
Top 3 companies account for 24.5% of total payments
Associated products mentioned in payments ›
ADCETRIS · AYVAKIT · BELEODAQ · BESREMI · Copiktra · DARZALEX · EMPLICITI · ENHERTU · ENJAYMO · EPKINLY · Enhertu · Erleada · FARXIGA · FOTIVDA · Fabhalta · IMBRUVICA · Imbruvica · KEYTRUDA · KISQALI · KRAZATI · LIBTAYO · LONSURF · LORBRENA · Lonsurf · MONJUVI · OPDIVO · Orserdu · PADCEV · PROMACTA · RETEVMO · Rubraca · SARCLISA · SIR-Spheres Microspheres · Tavalisse · Trodelvy · VERZENIO · VONJO · XPOVIO · XTANDI · Yescarta · ZYTIGA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (87%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $9 per 100 Medicare services performed
Looking for a medical oncology in Waco?
Compare medical oncologys in the Waco area by procedure volume, costs, and industry payment transparency.
Browse medical oncologys nearby

Geographic Context

Medical Oncologys within 10 mi
5
Per 100K population
1.9
County median income
$63,888
Nearest hospital
ASCENSION PROVIDENCE
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Okani is a mixed practice specialist, with above-average Medicare volume (top 27% in TX), and low-engagement industry engagement, with 19 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Okani experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Okani performed 20,400 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Okani receive payments from pharmaceutical companies?
Yes. Dr. Okani received a total of $2,917 from 39 companies across 68 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Okani's costs compare to other medical oncologys in Waco?
Dr. Okani's average Medicare payment per service is $5. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Okani) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →